share_log

T2 Biosystems Regains Compliance With Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance With Nasdaq Continued Listing Requirements

T2 Biosystems恢復了對納斯達克持續上市要求的合規性
T2 Biosystems ·  05/22 12:00

LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

馬薩諸塞州列剋星敦,2024年5月22日(GLOBE NEWSWIRE)——快速檢測敗血症致病原體和抗生素耐藥基因領域的領導者T2 Biosystems, Inc.(納斯達克股票代碼:TTOO)(“公司”)今天宣佈,它已於2024年5月21日收到納斯達克股票市場有限責任公司(“納斯達克股票代碼:TTOO”)(“公司”)的市值已恢復合規《納斯達克上市規則》第5550(b)(2)(“規則”)中規定的上市證券(“MVLS”)要求繼續在納斯達克資本市場上市。

On November 22, 2023, the Company received written notice from Nasdaq informing the Company that Nasdaq had determined to delist the Company, as it was not in compliance with the Nasdaq's MVLS requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days. On February 15, 2024, the Company appealed to the Nasdaq Hearings Panel for an exception to the MVLS requirement through May 20, 2024. On March 11, 2024, the Company received notice from the Nasdaq Hearings Panel that it had granted the Company an exception to the Nasdaq requirements, subject to the Company demonstrating compliance with the Rule on or before May 20, 2024.

2023年11月22日,公司收到納斯達克的書面通知,通知該公司,納斯達克決定將公司退市,因爲納斯達克沒有遵守納斯達克的MVLS要求,因爲它未能在連續30個工作日內將MVLS維持在至少3500萬美元的水平。2024年2月15日,該公司向納斯達克聽證小組提出上訴,要求在2024年5月20日之前豁免MVLS要求。2024年3月11日,公司收到納斯達克聽證小組的通知,稱其已批准公司對納斯達克要求的例外規定,前提是公司在2024年5月20日當天或之前證明遵守了該規則。

To regain compliance with the Rule, the Company was required to maintain a MVLS of at least $35 million for at least 10 consecutive trading days on or before May 20, 2024. This requirement was met on May 16, 2024, the tenth consecutive trading day when the MVLS was at least $35 million. The Company is currently in full compliance with NASDAQ continued listing requirements.

爲了恢復對該規則的遵守,公司必須在2024年5月20日當天或之前至少連續10個交易日將MVLS維持在至少3500萬澳元的水平。這一要求在2024年5月16日得到滿足,這是連續第十個交易日MVLS至少爲3500萬美元。該公司目前完全遵守納斯達克的持續上市要求。

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. For more information, please visit www.t2biosystems.com.

關於 T2 生物系統
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者,致力於通過幫助臨床醫生比以往任何時候都更快地有效治療患者來改善患者護理和降低護理成本。T2 Biosystems 的產品包括 T2Dx 儀器,T2Bertia 小組,T2Candida 面板,T2Restance 面板和 T2Biothreat Panel,由專有的 T2 磁共振 (T2MR) 提供動力) 技術。T2 Biosystems 擁有活躍的未來產品線,包括美國的 T2Resistance 小組、 耳念珠菌 測試,以及 T2Lyme 小組。欲了解更多信息,請訪問 www.t2biosystems.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about the Company's ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, including its ability to effect a reverse share split, as well as statements that include the words "expect," "intend," "plan", "believe", "project", "forecast", "estimate," "may," "should," "anticipate," and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) ability to continue as a going concern, or (v) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。本新聞稿中包含的所有與歷史事實無關的陳述均應被視爲前瞻性陳述,包括但不限於關於公司遵守納斯達克資本市場上市要求的能力(包括其進行反向股票拆分的能力)的陳述,以及包含 “預期”、“打算”、“計劃”、“相信”、“項目”、“預測”、“估計”、“可能” 等字樣的陳述” “應該”、“預測” 以及具有未來或前瞻性質的類似陳述。這些前瞻性陳述基於管理層當前的預期。這些陳述既不是承諾也不是保證,但涉及已知和未知的風險、不確定性和其他重要因素,這些因素可能導致實際結果、業績或成就與前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異,包括但不限於:(i) 無法 (a) 實現承諾、合同或產品的預期收益;(b) 成功執行戰略優先事項;(c) 將產品推向市場;(d) 擴大產品的使用或採用率;(e) 獲取客戶證言;(f) 準確預測增長假設;(g) 實現預期收入;(h) 產生預期的運營支出水平;或 (i) 增加客戶設施的高風險患者人數;(ii) 早期數據無法預測最終結果;(iii) 未能在預期的時間範圍內或根本沒有提交或獲得預期的美國食品藥品管理局申請或許可;或 (iv) 繼續經營的能力,或 (v) 項目1A下討論的因素。公司於2024年4月1日向美國證券交易委員會(SEC)提交的截至2023年12月31日年度的10-K表年度報告以及公司不時向美國證券交易委員會提交的其他文件中的 “風險因素”。這些和其他重要因素可能導致實際業績與本新聞稿中前瞻性陳述所示的結果存在重大差異。任何此類前瞻性陳述均代表管理層截至本新聞稿發佈之日的估計。儘管除非法律要求,否則公司可能會選擇在未來的某個時候更新此類前瞻性陳述,但它不承擔任何更新此類前瞻性陳述的義務,即使隨後發生的事件導致其觀點發生變化。因此,任何人都不應假設公司隨着時間的推移保持沉默意味着實際事件如此類前瞻性陳述中所明示或暗示的那樣得到證實。不應將這些前瞻性陳述視爲本新聞稿發佈之日後任何日期的公司觀點。

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

投資者聯繫人:
菲利普·特里普泰勒,吉爾馬丁集團
philip@gilmartinIR.com 415-937-5406

Primary Logo

Source: T2 Biosystems, Inc.

來源:T2 Biosystems, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論